Author’s response to reviews

Title: Real-Life Assessment of Aripiprazole Monthly (Abilify Maintena) in Schizophrenia: A Canadian Naturalistic Non-Interventional Prospective Cohort Study

Authors:

Sally Mustafa (sally.mustafa@douglas.mcgill.ca)
Joanna Bougie (jkb@lundbeck.com)
Maia Miguelez (maia.miguelez@otsuka-ca.com)
Guerline Clerzius (gucl@lundbeck.com)
Emmanouil Rampakakis (ERampakakis@jssresearch.com)
Jean Proulx (jepr@lundbeck.com)
Ashok Malla (ashok.malla@mcgill.ca)

Version: 3 Date: 03 Apr 2019

Author’s response to reviews:

BPSY-D-18-00965R2

Real-Life Assessment of Aripiprazole Monthly (Abilify Maintena) in Schizophrenia: A Canadian Naturalistic Non-Interventional Prospective Cohort Study

Sally Mustafa, PhD; Joanna Bougie; Maia Miguelez; Guerline Clerzius; Emmanouil Rampakakis; Jean Proulx; Ashok Malla

BMC Psychiatry

Dear Dr Malla,

Your manuscript "Real-Life Assessment of Aripiprazole Monthly (Abilify Maintena) in Schizophrenia: A Canadian Naturalistic Non-Interventional Prospective Cohort Study" (BPSY-D-18-00965R2) has been assessed by our reviewers. Based on these reports, and my own assessment as Editor, I am pleased to inform you that it is potentially acceptable for publication in BMC Psychiatry, once you have carried out some essential revisions.
1. Thank you for including the date of registration alongside the trial registration number at the end of the Abstract section. If the date of registration is after the date that the first participant was recruited, please also state ‘retrospectively registered’.

The study was posted on May 6, 2014 which was prior to the date of the first patient informed consent (May 26, 2014). Therefore, the study was not retrospectively registered.

2. Thank you for including a Funding heading for the Declarations section. Please also state the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. Please note that the “role” of any given funding body specifies any function beyond the direct funding of aspects of the research or presentation of the manuscript.

This statement has been added: “This study was funded by Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc. Lundbeck and Otsuka Canada participated in the design of the study in consultation with A.M. (senior author). Data collection was coordinated by JSS and collected by individual clinician investigators at the respective sites.”

3. Please remove the cover letter and the response to reviewers from the file inventory, as they are no longer needed at this stage of the editorial process.

Done

4. When submitting your revised manuscript please ensure you do so as a single clean copy without any tracked changes, colored or highlighted text, as these are no longer required at this stage of the editorial process.

Done

Once you have made the necessary corrections, please submit a revised manuscript online at:

https://www.editorialmanager.com/bpsy/

If you have forgotten your password, please use the 'Send Login Details' link on the login page at https://www.editorialmanager.com/bpsy/. For security reasons, your password will be reset.
A point-by-point response letter must accompany your revised manuscript. This letter must provide a detailed response to each reviewer/editorial point raised, describing exactly what amendments have been made to the manuscript text and where these can be viewed (e.g. Methods section, line 12, page 5). If you disagree with any comments raised, please provide a detailed rebuttal to help explain and justify your decision.

At this stage, we ask that you submit a clean version of your manuscript and do not include track changes or highlighting.